期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

Synthesis and biological evaluation of echinocystic acid derivatives as HCV entry inhibitors 被引量：3

Synthesis and biological evaluation of echinocystic acid derivatives as HCV entry inhibitors
原文传递
导出
摘要 A series of echinocystic acid （EA） 28-COOH derivatives was synthesized, and their anti-HCV entry activity was evaluated by HCVpp and VSVpp entry assay. It was found that some of them showed moderate anti-HCV entry activity, especially compound 12, and these modifications also removed the undesired hemolytic effect. A series of echinocystic acid （EA） 28-COOH derivatives was synthesized, and their anti-HCV entry activity was evaluated by HCVpp and VSVpp entry assay. It was found that some of them showed moderate anti-HCV entry activity, especially compound 12, and these modifications also removed the undesired hemolytic effect.
作者 Fei Yu Qi wang Han Wang Long-Long Si Jia-Xin Liu XU Han Su-Long Xiao Li-He Zhang De-Min Zhou
机构地区 Medical Faculty of Kunming University of Science and Technology State Key Laboratory of Natural and Biomimetic Drugs
出处 《Chinese Chemical Letters》 SCIE CAS CSCD 2016年第5期711-713,共3页 中国化学快报（英文版）
基金 supported by the National Natural Science Foundation of China (Nos. 81373271 and 81361168002) OpenFund Program of the State Key Laboratory of Natural and Biomimetic Drugs (No. K20150214) Yunnan Basic Research Project (No. 14051789)
关键词 Triterpene Echinocystic acid HCV entry inhibitors Hemolysis Triterpene Echinocystic acid HCV entry inhibitors Hemolysis
分类号 R914.5 [医药卫生—药物化学] R96 [医药卫生—药理学]
  • 相关文献

参考文献15

  • 1T. Sy, M.M.Jamal, Epidemiology of hepatitis C virus (HCV) infection, Int.J. Med. Sci. 3 (2006) 41-46.
  • 2C.W. Shepard, L. Finelli, M.J. Alter, Global epidemiology of hepatitis C virus infection, Lancet Infect. Dis. 5 (2005) 558-567.
  • 3C. Sheridan, New Merck and Vertex drugs raise standard of care in hepatitis C, Nat. Biotechnol. 29 (2011) 553-554.
  • 4M. Fried, M. Shiffman, K. Reddy, et al., Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection, New Engl. J. Med. 347 (2002) 975-982.
  • 5A.M. Di Bisceglie, J. McHutchison, C.M. Rice, New therapeutic strategies for hepatitis C, Hepatology 35 (2002) 224-231.
  • 6A. Thompson, J. McHutchison, Antiviral resistance and specifically targeted therapy for HCV (STAT-C), J. Viral Hepatitis 16 (2009) 377-387.
  • 7F. Wong-Staal, A.J. Syder, J.F. McKelvy, Targeting HCV entry for development of therapeutics, Viruses 2 (2010) 1718-1733.
  • 8F. Yu, Q. Wang, Z. Zhang, et al., Development ofoleanane-type triterpenes as a new class of HCV nntry inhibitors, J. Med. Chem. 56 (2013) 4300-4319.
  • 9G,K. Mittapalli, A. Jackson, F. Zhao, et aL, Discovery of highly potent small molecule hepatitis C virus entry inhibitors, Bioorg. Med. Chem. Lett. 21 (2011) 6852-6855.
  • 10F. Yu, Y. Peng, Q. Wang, et al., Development of bivalent oleanane-type triterpenes as potent HCV entry inhibitors, Eur. J. Med. Chem, 77 (2014) 258-268.

同被引文献33

引证文献3

二级引证文献12

Chinese Chemical Letters
2016年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部